The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Autologous Bone Marrow-Derived Mesenchymal Stromal Cells for the Treatment of Allograft Rejection After Renal Transplantation: Results of a Phase I Study
Open accessAbstract
Despite excellent short-term results, long-term survival of transplanted kidneys has not improved accordingly. Although alloimmune responses and calcineurin inhibitor-related nephrotoxicity have been identified as main drivers of fibrosis, no effective treatment options have emerged. In this perspective, mesenchymal stromal cells (MSCs) are an interesting candidate because of their immunosuppressive and regenerative properties. Of importance, no other clinical studies have investigated their effects in allograft rejection and fibrosis. We performed a safety and feasibility study in kidney allograft recipients to whom two intravenous infusions (1 million cells per kilogram) of autologous bone marrow (BM) MSCs were given, when a protocol renal biopsy at 4 weeks or 6 months showed signs of rejection and/or an increase in interstitial fibrosis/tubular atrophy (IF/TA). Six patients received MSC infusions. Clinical and immune monitoring was performed up to 24 weeks after MSC infusions. MSCs fulfilled the release criteria, infusions were well-tolerated, and no treatment-related serious adverse events were reported. In two recipients with allograft rejection, we had a clinical indication to perform surveillance biopsies and are able to report on the potential effects of MSCs in rejection. Although maintenance immunosuppression remained unaltered, there was a resolution of tubulitis without IF/TA in both patients. Additionally, three patients developed an opportunistic viral infection, and five of the six patients displayed a donor-specific downregulation of the peripheral blood mononuclear cell proliferation assay, not reported in patients without MSC treatment. Autologous BM MSC treatment in transplant recipients with subclinical rejection and IF/TA is clinically feasible and safe, and the findings are suggestive of systemic immunosuppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Solez, K., Colvin, R., Racusen, L., Sis, B., Halloran, P., Birk, P., Campbell, P., Cascalho, M., Collins, A., Demetris, A., et al. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01688.x · Cited by 1,082
Mesenchymal Stromal Cells: Current Understanding and Clinical Status
Salem, H. K., & Thiemermann, C. (2010) · Stem Cells · doi:10.1002/stem.269 · Cited by 915
Strategies to Improve Long-Term Outcomes after Renal Transplantation
Pascual, M., Theruvath, T., Kawai, T., Tolkoff-Rubin, N., & Cosimi, A. B. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011295 · Cited by 844
Duijvestein, M., Vos, A. C. W., Roelofs, H., Wildenberg, M. E., Wendrich, B. B., Verspaget, H. W., Kooy-Winkelaar, E. M. C., Koning, F., Zwaginga, J. J., Fidder, H. H., et al. (2010) · Gut · doi:10.1136/gut.2010.215152 · Cited by 622
Self-citationTan, J., Wu, W., Xu, X., Liao, L., Zheng, F., Messinger, S., Sun, X., Chen, J., Yang, S., Cai, J., et al. (2012) · JAMA · doi:10.1001/jama.2012.316 · Cited by 553
Morigi, M., Introna, M., Imberti, B., Corna, D., Abbate, M., Rota, C., Rottoli, D., Benigni, A., Perico, N., Zoja, C., et al. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0795 · Cited by 381
Concise Review: Hitting the Right Spot with Mesenchymal Stromal Cells
Tolar, J., Le Blanc, K., Keating, A., & Blazar, B. R. (2010) · Stem Cells · doi:10.1002/stem.459 · Cited by 376
Mesenchymal Stromal Cells: Facilitators of Successful Transplantation?
English, K., French, A., & Wood, K. J. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.09.009 · Cited by 303
Perico, N., Casiraghi, F., Introna, M., Gotti, E., Todeschini, M., Cavinato, R. A., Capelli, C., Rambaldi, A., Cassis, P., Rizzo, P., et al. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04950610 · Cited by 297
Ninichuk, V., Gross, O., Segerer, S., Hoffmann, R., Radomska, E., Buchstaller, A., Huss, R., Akis, N., Schlöndorff, D., & Anders, H.-J. (2006) · Kidney International · doi:10.1038/sj.ki.5001521 · Cited by 283
Ge, W., Jiang, J., Baroja, M. L., Arp, J., Zassoko, R., Liu, W., Bartholomew, A., Garcia, B., & Wang, H. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02721.x · Cited by 271
Immunomodulatory Effects of Mesenchymal Stem Cells in a Rat Organ Transplant Model
Inoue, S., Popp, F. C., Koehl, G. E., Piso, P., Schlitt, H. J., Geissler, E. K., & Dahlke, M. H. (2006) · Transplantation · doi:10.1097/01.tp.0000209919.90630.7b · Cited by 252
Casiraghi, F., Azzollini, N., Todeschini, M., Cavinato, R. A., Cassis, P., Solini, S., Rota, C., Morigi, M., Introna, M., Maranta, R., et al. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04115.x · Cited by 168
Franquesa, M., Herrero, E., Torrás, J., Ripoll, È., Flaquer, M., Gomà, M., Lloberas, N., Anegón, I., Cruzado, J. M., Grinyo, J. M., et al. (2012) · Stem Cells and Development · doi:10.1089/scd.2012.0096 · Cited by 132
Multipotent mesenchymal stromal cell therapy in renal disease and kidney transplantation
Reinders, M. E. J., Fibbe, W. E., & Rabelink, T. J. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp552 · Cited by 96
Self-citationGroningen, M. C. R.-V., Scholten, E. M., Lelieveld, P. M., Rowshani, A. T., Baelde, H. J., Bajema, I. M., Florquin, S., Bemelman, F. J., de Heer, E., de Fijter, J. W., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005080891 · Cited by 74
Self-citation
Cited by
Stem Cell Therapies in Clinical Trials: Progress and Challenges
Trounson, A., & McDonald, C. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.06.007 · Cited by 1,468
Mesenchymal stem cells and immunomodulation: current status and future prospects
Gao, F., Chiu, S. M., Motan, D. A. L., Zhang, Z., Chen, L., Ji, H.-L., Tse, H.-F., Fu, Q.-L., & Lian, Q. (2016) · Cell Death & Disease · doi:10.1038/cddis.2015.327 · Cited by 1,121
Weiss, A. R. R., & Dahlke, M. H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01191 · Cited by 695
Biological functions of mesenchymal stem cells and clinical implications
Naji, A., Eitoku, M., Favier, B., Deschaseaux, F., Rouas-Freiss, N., & Suganuma, N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03125-1 · Cited by 624
Mesenchymal Stem Cells Deliver Exogenous MicroRNA-let7c via Exosomes to Attenuate Renal Fibrosis
Wang, B., Yao, K., Huuskes, B. M., Shen, H.-H., Zhuang, J., Godson, C., Brennan, E. P., Wilkinson-Berka, J. L., Wise, A. F., & Ricardo, S. D. (2016) · Molecular Therapy · doi:10.1038/mt.2016.90 · Cited by 379
Metadata
- Authors
- Reinders, M. E. J., de Fijter, J. W., Roelofs, H., Bajema, I. M., de Vries, D. K., Schaapherder, A. F., Claas, F. H. J., van Miert, P. P. M. C., Roelen, D. L., van Kooten, C., Fibbe, W. E., & Rabelink, T. J.
- Venue
- Stem Cells Translational Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-01-24
- Volume
- 2
- Issue
- 2
- Pages
- 107-111
- ISSN
- 2157-6564 (ISSN-L)
- 2157-6580
- OpenAlex
- W2149285411
- Cited by
- 339
- References
- 16
- FWCI
- 17.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.